Contact   |   Login
Human Pharmaceuticals Banner Image

Active Pharmaceutical Ingredients (APIs)*

Pharmapex's Human Pharmaceuticals Department (HPD) offers a rich portfolio of hundreds of active pharmaceutical ingredients (APIs) with superior quality, excellent customer service and unparalleled IP assets. Our group's profound partnership and investment in research & development generates a steady flow of APIs, enabling a timely introduction of products to the market. Understanding the dynamics of the cost conscious market, about half of this R&D is dedicated to cost reduction through process efficiency and automation, enabling our customers to remain competitive in the marketplace.

We continuously endeavor to provide our clients with the newest APIs for ongoing research and product development efforts as well as commercial production. Our products include a diverse array of APIs manufactured in facilities that comply with Good Manufacturing Practices (GMP’s) and are approved by US-FDA. Through years, our group has also received the approval of other pharmaceutical regulatory agencies such as Australia TGA, German Health Authority Hamburg, Cofepris Mexico, and Korea Health Authority.

HPD constantly aims to provide the highest technical support and full regulatory documentation, such as US-DMF/TDP/CTD/E-DMF/CEP, even for the most recently approved APIs originating from our US-FDA approved production facilities. Many of our APIs are suitable for Paragraph IV challenges/early launch in regulated markets as they are manufactured via non-infringing routes of synthesis.

Major Therapeutic Areas:




† Not all products referred to on this site are available in all countries and our products are subject to different regulatory requirements depending on the country of use. Consequently, certain sections of this site may be indicated as being intended only for users in specific countries. Some of the products may also be marketed under different trade names.

You should not construe anything on this site as a promotion or solicitation for any product or for the use of any product that is not authorized by the laws and regulations of your country of residence. For inquiries about the availability of any specific product in your country, you may simply contact us at humanpharma@PharmapexUSA.com.

*Products currently covered by valid US Patents may be offered for R&D use in accordance with 35 USC 271(e)+A13(1). Any patent infringement and resulting liability is solely at buyer risk.



Quick Contact

Recent Newsletters:

Issue #: 211 – AHD:
by Animal Health Department

Issue #: 214 – CHD:
by Consumer Health Department

Issue #: 224 – F&F:
by Food & Feed Business Unit
Press Releases and Latest News:
PND releases a 200+ page catalog for 2016
Pharmapex's Nutrition Department releases an extensive 2016 catalog for dietary supplements.
Pharmapex's novel mastitis treatment offers hope to world farmers
Efficient feed-based mastitis treatment boosts livestock health with a unique microencapsulated technology.
FDA approves Farxiga to treat type 2 diabetes
The U.S. FDA today approved Farxiga (dapaglifozin) tablets to improve glycemic control, along with diet and exercise, in adults with type 2 diabetes.
© 2017, Pharmapex USA, A member of Apex Group of Companies, All Rights Reserved.